Related Experiment Video

Updated: May 14, 2025

SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs
07:39

SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs

Published on: June 28, 2019

23.6K

SGLT2 inhibitors as a novel senotherapeutic approach

Zeynep Elif Yesilyurt-Dirican1,2, Ce Qi2, Yi-Chian Wang2

  • 1Department of Pharmacology, Faculty of Pharmacy, Gazi University, Ankara, Türkiye.

Npj Aging
|May 10, 2025
PubMed

Insights

Sodium-glucose co-transporter 2 (SGLT2) inhibitors, initially for diabetes, show promise as senotherapeutics. These drugs may target cellular senescence and its associated secretory phenotype (SASP), offering new avenues for aging and disease treatment.

Area of Science:

  • Gerontology and Molecular Biology
  • Pharmacology and Therapeutics

Background:

  • Cellular senescence, the irreversible halt in cell division, contributes to aging and chronic diseases via the senescence-associated secretory phenotype (SASP).
  • Senotherapeutic strategies aim to mitigate aging and disease by targeting senescent cells or their SASP.
  • Sodium-glucose co-transporter 2 (SGLT2) inhibitors are a class of anti-diabetic drugs with known cardiovascular and renal protective effects.

Purpose of the Study:

  • To review the emerging senotherapeutic potential of Sodium-glucose co-transporter 2 (SGLT2) inhibitors.
  • To examine the latest research linking SGLT2 inhibitors to the inhibition of cellular senescence and SASP.

Main Methods:

  • Literature review of recent scientific publications and clinical studies.
  • Analysis of data on SGLT2 inhibitors' effects on cellular senescence markers and SASP.
  • Synthesis of evidence regarding the therapeutic implications for aging and age-related diseases.

Main Results:

  • SGLT2 inhibitors demonstrate potential in inhibiting cellular senescence.
  • These drugs may counteract the pro-inflammatory effects of the senescence-associated secretory phenotype (SASP).
  • Evidence suggests SGLT2 inhibitors could be repurposed as senotherapeutics.

Conclusions:

  • SGLT2 inhibitors represent a promising therapeutic avenue for targeting cellular senescence and aging.
  • Further research into SGLT2 inhibitors' senotherapeutic mechanisms and clinical efficacy is warranted.
  • Repurposing SGLT2 inhibitors could offer novel strategies for managing age-related pathologies.

More Related Videos

Spectrophotometric Screening for Potential Inhibitors of Cytosolic Glutathione S-Transferases14:57

Spectrophotometric Screening for Potential Inhibitors of Cytosolic Glutathione S-Transferases

Published on: October 10, 2020

14.3K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

3.9K

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
270
Secondary Active Transport01:32

Secondary Active Transport

One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme "pump" embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
6.6K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
141
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.2K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
136